Standard BioTools downgraded to Hold from Buy at TD Cowen

TD Cowen downgraded Standard BioTools (LAB) to Hold from Buy with a price target of $1.55, down from $1.60, post the Q2 report. The company sees a lower growth outlook for the core business and less visibility following the sale of SomaLogic. The company’s core business trends will continue to be challenged amid macro headwinds, the analyst tells investors in a research note.